AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33427211 — intervention group
Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitors (high matching score)
Number of subjects: 40
Study 33427211 — intervention group
Group type: COMPARATOR
Intervention: CDK4/6 inhibitors (low matching score)
Number of subjects: 40
Study 33427685 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin-containing medication
Number of subjects: 300
Study 33427685 — intervention group
Group type: EXPERIMENTAL
Intervention: my ePRO app
Number of subjects: 300
Study 33427689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 4
Study 33427767 — intervention group
Group type: EXPERIMENTAL
Intervention: Just4Us intervention (counselor-navigator and text message support)
Number of subjects: 0
Study 33427818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive implementation support during the pilot phase
Number of subjects: 0
Study 33427818 — intervention group
Group type: COMPARATOR
Intervention: Non-focus districts
Number of subjects: 0
Study 33427818 — intervention group
Group type: COMPARATOR
Intervention: Formerly focus districts
Number of subjects: 0
Study 33427818 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall change from round 2-9 in focus districts
Number of subjects: 0
Study 33428174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 33428174 — intervention group
Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study 33428222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative MRI (iMRI)
Number of subjects: 322
Study 33428222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence-guided surgery with 5-ALA
Number of subjects: 322
Study 33428222 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigation
Number of subjects: 322
Study 33428222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative MRI (iMRI) (second trial)
Number of subjects: 322
Study 33428248 — intervention group
Group type: EXPERIMENTAL
Intervention: Micra implant with concomitant AVNA
Number of subjects: 192
Study 33428248 — intervention group
Group type: COMPARATOR
Intervention: Micra patients without AVNA
Number of subjects: 192
Study 33428522 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33428559 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of violence (psychological abuse, verbal abuse, emotional maltreatment)
Number of subjects: 41
Study 33428559 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV clinic settings addressing verbal abuse and emotional maltreatment
Number of subjects: 41
Study 33428559 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring
Number of subjects: 41
Study 33428559 — intervention group
Group type: COMPARATOR
Intervention: Standard discipline practices (physical violence from caregivers and teachers)
Number of subjects: 41
Study 33428617 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-9
Number of subjects: 903
Study 33428617 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-10
Number of subjects: 903
Study 33428617 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 903
Study 33428617 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-9 with breastfeeding difficulties
Number of subjects: 903
Study 33428617 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-10 with breastfeeding difficulties
Number of subjects: 903
Study 33428617 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-9 without breastfeeding difficulties
Number of subjects: 903
Study 33428617 — intervention group
Group type: EXPERIMENTAL
Intervention: Steps 1-10 without breastfeeding difficulties
Number of subjects: 903
Study 33428771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib with a 1-hour interval before taking gastric acid suppressants (GAS)
Number of subjects: 0
Study 33428771 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib without a specified interval before taking gastric acid suppressants (GAS)
Number of subjects: 0
Study 33429092 — intervention group
Group type: EXPERIMENTAL
Intervention: DETOUR procedure using TORUS stent grafts
Number of subjects: 78
Study 33429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline pathogenic/likely pathogenic variants (P/LPVs) in cancer susceptibility genes identified in patients with PDAC.
Number of subjects: 549
Study 33429865 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline pathogenic/likely pathogenic variants (P/LPVs) in homologous recombination repair (HRR) genes identified in patients with PDAC.
Number of subjects: 549
Study 33430634 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT±CTA alone in the early window (n=332)
Number of subjects: 2008
Study 33430634 — intervention group
Group type: EXPERIMENTAL
Intervention: NCCT±CTA and CTP in the early window (n=373)
Number of subjects: 2008
Study 33430634 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended window endovascular stroke therapy
Number of subjects: 2008
Study 33430796 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIZIG
Number of subjects: 303
Study 33430807 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective measure of Post-Traumatic Growth (PTG)
Number of subjects: 187
Study 33430807 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective measure of Post-Traumatic Growth (PTG)
Number of subjects: 187
Study 33430807 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD scale administered at five-month follow-up
Number of subjects: 187
Study 33430816 — intervention group
Group type: EXPERIMENTAL
Intervention: Close Collaboration with Parents intervention
Number of subjects: 170
Study 33430820 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgery
Number of subjects: 28
Study 33430820 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 28
Study 33430820 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 28
Study 33430930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm electrical activity (EAdi) monitoring after intubation
Number of subjects: 69
Study 33430930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative agents (propofol and fentanyl)
Number of subjects: 69
Study 33430930 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 69
Study 33430930 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse triggering
Number of subjects: 69
Study 33430930 — intervention group
Group type: COMPARATOR
Intervention: General severity, oxygenation, renal and hepatic function, reason for intubation
Number of subjects: 69
Study 33431018 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) Antipsychotic Medication Decision Aid
Number of subjects: 100
Study 33431018 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 33431027 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain CareNotes (BCN) mobile telehealth system
Number of subjects: 60
Study 33431027 — intervention group
Group type: COMPARATOR
Intervention: Usual care comparator
Number of subjects: 60
Study 33431248 — intervention group
Group type: EXPERIMENTAL
Intervention: Life satisfaction
Number of subjects: 1904
Study 33431248 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 1904
Study 33431248 — intervention group
Group type: COMPARATOR
Intervention: Moderate to Severe depression profile
Number of subjects: 1904
Study 33431248 — intervention group
Group type: COMPARATOR
Intervention: Mild depression profile
Number of subjects: 1904
Study 33431488 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific guideline deviation for atrial fibrillation, congestive heart failure, chronic kidney disease, chronic obstructive pulmonary disorder, depression, diabetes, dyslipidaemia, hypertension and ischaemic heart disease.
Number of subjects: 204
Study 33431488 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-care guideline deviation.
Number of subjects: 204
Study 33431488 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 204
Study 33431488 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 204
Study 33431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised echocardiographic approach
Number of subjects: 5998
Study 33431619 — intervention group
Group type: COMPARATOR
Intervention: Traditional short-axis evaluation
Number of subjects: 5998
Study 33431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 5998
Study 33431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative medical treatment
Number of subjects: 5998
Study 33431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of AAOCA
Number of subjects: 5998
Study 33431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of AAOCA
Number of subjects: 5998
Study 33431619 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 5998
Study 33431660 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRP-1
Number of subjects: 0
Study 33431660 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRP-2
Number of subjects: 0
Study 33431660 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRP-1 and SIRP-2
Number of subjects: 0
Study 33431814 — intervention group
Group type: EXPERIMENTAL
Intervention: High immune-ITH
Number of subjects: 0
Study 33431814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low immune-ITH
Number of subjects: 0
Study 33431814 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-ITH
Number of subjects: 0
Study 33431949 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive stimuli in dyslexic children
Number of subjects: 34
Study 33431949 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive stimuli in age-matched controls
Number of subjects: 34
Study 33431949 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive acuity
Number of subjects: 34
Study 33432540 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar etanercept 25 mg twice weekly or 50 mg once weekly
Number of subjects: 583
Study 33432540 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar etanercept
Number of subjects: 583
Study 33432547 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR341402 insulin aspart (SAR-Asp)
Number of subjects: 597
Study 33432547 — intervention group
Group type: COMPARATOR
Intervention: NN-Asp (NovoLog®/NovoRapid® insulin aspart)
Number of subjects: 597
Study 33432705 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-122
Number of subjects: 235
Study 33432705 — intervention group
Group type: EXPERIMENTAL
Intervention: K18
Number of subjects: 235
Study 33432705 — intervention group
Group type: EXPERIMENTAL
Intervention: DILI cases
Number of subjects: 235
Study 33433145 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment (42 patients)
Number of subjects: 62
Study 33433145 — intervention group
Group type: COMPARATOR
Intervention: Not treated (20 patients)
Number of subjects: 62
Study 33433149 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal power cycling (PC) training for 8 weeks, 15 min per session, 3 times per week
Number of subjects: 39
Study 33433155 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium/high-risk genotype (HFE SNPs rs1800562 and rs1799945)
Number of subjects: 100
Study 33433355 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofuginone (HF) at 50 nM concentration
Number of subjects: 0
Study 33433355 — intervention group
Group type: COMPARATOR
Intervention: TGF-β1 (pro-fibrotic agent)
Number of subjects: 0
Study 33433485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-assisted mode
Number of subjects: 23
Study 33433485 — intervention group
Group type: COMPARATOR
Intervention: Active mode
Number of subjects: 23
Study 33433714 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors influencing consultation delay
Number of subjects: 14
Study 33433714 — intervention group
Group type: EXPERIMENTAL
Intervention: Logical model for change
Number of subjects: 14
Study 33433743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies involving immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1)
Number of subjects: 0
Study 33433743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0
Study 33433743 — intervention group
Group type: EXPERIMENTAL
Intervention: Future approaches involving bispecific antibodies and CAR-T cells
Number of subjects: 0
Study 33433785 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Glycopyrronium Tosylate (GT) applied once daily for 5 days in phase I study; 0.8-3.2% GT applied once daily for 4 weeks in phase II studies.
Number of subjects: 0
Study 33433785 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Glycopyrronium Tosylate (GT) applied once daily for 4 weeks in phase II studies.
Number of subjects: 0
Study 33433785 — intervention group
Group type: COMPARATOR
Intervention: Oral Glycopyrrolate administered every 8 hours for 15 days in phase I study.
Number of subjects: 0
Study 33433896 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD-CIM Observer-Reported Outcome (ObsRO) measure
Number of subjects: 98
Study 33433896 — intervention group
Group type: EXPERIMENTAL
Intervention: GHD-CIM ObsRO measure
Number of subjects: 98
Study 33434110 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated anterior circulation CT angiographic clot detection platform
Number of subjects: 0
Study 33434110 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals without LVO)
Number of subjects: 0
Study 33434161 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF1 therapy
Number of subjects: 242
Study 33434221 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid immunomodulatory therapy
Number of subjects: 52
Study 33434221 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10 measurements
Number of subjects: 52
Study 33434221 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10 levels exceeding 1,000 pg/mL
Number of subjects: 52
Study 33434290 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term bisphosphonate therapy in patients with atypical femur fracture (AFF)
Number of subjects: 52
Study 33434290 — intervention group
Group type: COMPARATOR
Intervention: Long-term bisphosphonate therapy in patients without atypical femur fracture (non-AFF)
Number of subjects: 52
Study 33434314 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 μg abaloparatide daily
Number of subjects: 23
Study 33434453 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous Telepsychiatry Interviewer Training
Number of subjects: 0
Study 33435412 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker testing and treatment for TRK fusion cancer; specific details on dosage and duration not available.
Number of subjects: 0
Study 33435412 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control treatment not available.
Number of subjects: 0
Study 33435695 — intervention group
Group type: EXPERIMENTAL
Intervention: %ddcfDNA measurement
Number of subjects: 171
Study 33435695 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rejection)
Number of subjects: 171
Study 33435695 — intervention group
Group type: EXPERIMENTAL
Intervention: %ddcfDNA monitoring
Number of subjects: 171
Study 33435732 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated devices
Number of subjects: 0
Study 33435732 — intervention group
Group type: COMPARATOR
Intervention: Nondrug-coated devices
Number of subjects: 0
Study 33435865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CD4 levels in COVID-19 patients
Number of subjects: 395
Study 33435865 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 395
Study 33435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based obesity intervention
Number of subjects: 100
Study 33435887 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients undergoing surgery
Number of subjects: 80
Study 33435887 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with symptoms
Number of subjects: 80
Study 33435887 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients without symptoms
Number of subjects: 80
Study 33435887 — intervention group
Group type: COMPARATOR
Intervention: Overall surgical activities during the pandemic
Number of subjects: 80
Study 33435926 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 100
Study 33435974 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic spectral imaging (DSI) color map directed biopsy
Number of subjects: 529
Study 33435974 — intervention group
Group type: COMPARATOR
Intervention: All four cervical biopsies
Number of subjects: 529
Study 33435973 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chest CT
Number of subjects: 165
Study 33436007 — intervention group
Group type: EXPERIMENTAL
Intervention: NNI-362, an allosteric p70S6 kinase stimulator
Number of subjects: 0
Study 33436012 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary thrombosis prophylaxis
Number of subjects: 2208
Study 33436012 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of PE-LDVT
Number of subjects: 2208
Study 33436012 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of NLDVT
Number of subjects: 2208
Study 33436021 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual-based nutritional-lifestyle intervention
Number of subjects: 164
Study 33436021 — intervention group
Group type: COMPARATOR
Intervention: Collective-based nutritional-lifestyle intervention
Number of subjects: 164
Study 33436023 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab 3 mg/kg intravenously every 2 weeks until disease progression or intolerable toxicity
Number of subjects: 102
Study 33436023 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab in patients with PD-L1 expression ≥ 50%
Number of subjects: 102
Study 33436023 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab in patients with PD-L1 expression < 50%
Number of subjects: 102
Study 33436023 — intervention group
Group type: EXPERIMENTAL
Intervention: Geptanolimab
Number of subjects: 102
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Texting reporting method
Number of subjects: 30
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Calling reporting method
Number of subjects: 30
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-falls reporting
Number of subjects: 30
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual falls reporting
Number of subjects: 30
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance recovery manoeuvres
Number of subjects: 30
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment and retention
Number of subjects: 30
Study 33436025 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of near-falls
Number of subjects: 30
Study 33436090 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week behavioral change intervention
Number of subjects: 30
Study 33436090 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 33436397 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-target stool DNA (mt-sDNA) test
Number of subjects: 816
Study 33436455 — intervention group
Group type: EXPERIMENTAL
Intervention: Average annual medication costs per patient
Number of subjects: 4
Study 33436455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of medication to total health care costs
Number of subjects: 4
Study 33436455 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of prescribing
Number of subjects: 4
Study 33436455 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication classes
Number of subjects: 4
Study 33436493 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 20 mg and 10 mg (combined)
Number of subjects: 421
Study 33436493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 33436675 — intervention group
Group type: EXPERIMENTAL
Intervention: MTf-targeting antibody-drug conjugate (ADC)
Number of subjects: 0
Study 33436675 — intervention group
Group type: EXPERIMENTAL
Intervention: Murine unconjugated Fab fragment (SC57.32)
Number of subjects: 0
Study 33436744 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg taken once daily for three months
Number of subjects: 235
Study 33436812 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 21 concentration in patients at ICU admission
Number of subjects: 112
Study 33436812 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF 21 concentration at 48 hours post-arrest
Number of subjects: 112
Study 33436812 — intervention group
Group type: EXPERIMENTAL
Intervention: Average FGF 21 concentration during the first 72 hours
Number of subjects: 112
Study 33436812 — intervention group
Group type: COMPARATOR
Intervention: FGF 21 concentration in controls
Number of subjects: 112
Study 33436812 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological outcome assessment
Number of subjects: 112
Study 33437832 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily IVR call reminders with self-management support messaging, plus a weekly IVR adherence assessment
Number of subjects: 362
Study 33437832 — intervention group
Group type: COMPARATOR
Intervention: Attention control with only weekly IVR adherence assessment
Number of subjects: 362
Study 33437832 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily IVR call reminders
Number of subjects: 362
Study 33437832 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 362
Study 33437997 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolaemia (FH)
Number of subjects: 5022
Study 33437997 — intervention group
Group type: COMPARATOR
Intervention: Non-affected relatives (NAR)
Number of subjects: 5022
Study 33438069 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5-15 mg/kg) administered every 2 or 3 weeks, with or without chemotherapy
Number of subjects: 71
Study 33438092 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Expiratory Pressure (MEP) assessment before extubation after a successful spontaneous breathing trial.
Number of subjects: 124
Study 33438092 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Inspiratory Pressure (MIP) was included in the multivariate model.
Number of subjects: 124
Study 33438092 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEP and MIP measurements.
Number of subjects: 124